Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Sorry nematode, I'm not a boxing fan, I prefer tennis. I thought share bulletin boards were all about trying to make money for your fellow men/women, and enjoying an open debate. How naive of me. You will be pleased to know that I will not be posting on this thread again, irrespective of whether or not this share goes to 2, or 75p. Good luck with your share dealing, and good luck to all the other BPRG holders.

Thanks scottie.Can't understand why as a non holder you bothered in the first instance.I would buy more at these ridiclously low prices Scottie before the leap to 2.00 after the brokers note.

Someone already said that .... at 140p , 130p ,120p ....

Hey Bullie , that was lucky getting in the day before Shares tipped them :-)

Bungalow.

Bought at 106 and 108. It sometimes isn't the theory it is the B. market

PS I think it will go back up to 150-60 in spite of for sale notice in IC

Im sure you are right Fred. All the speculators should be out by now, think it will return to a nice gentle upwards path.

cheers GF.

Found this on another thread this evening,..........The item in question comes from, Weekly market report

analyst@thewrongprice.com.
http://www.thewrongprice.com/


Bioprogress steps up a gear

Bioprogress (BPRG), which is developing novel ways of delivering drugs,
released its first set of final figures since moving from Nasdaq to AIM
last May. The numbers, showing a million loss on turnover of ,000,
were pretty irrelevant compared with two accompanying announcements, which
should transform the group?s fortunes.

Chief executive Graham Hind has pulled off an intriguing deal to buy the
principal assets of Florida-based Aquafilm for an initial $3.5 million and
a possible $7.5 million depending on the performance of the business.

Most of this will be financed by a placing with UK institutions raising
5 million net at 110p a share. At the end of 2003 the company already
had million net cash, so the group now looks more than adequately
funded for the next few years.

More importantly Aquafilm is already producing serious revenues of $4
million annually, thanks to agreements to make edible films for use in
nutritional products, such as vitamins, and food products. The company has
contracts with Boots in the UK to make Vitamin C strips and Wrigleys to
produce breath freshener that dissolves in the mouth.

Hind?s plan is to upgrade the facility so that soluble films for use by
drug companies can be made there as well. This should fast track
BioProgress?s business plan, which is either to produce in-house these
novel delivery systems replacing tablet doses, or else licence out its
technology.

On that front the group also revealed that it has signed a global licensing
deal with one of the world?s leading producer of over-the-counter medicines
and nutritional items, using its Xgel Tabwrap technology. This will replace
traditional tablets with non-gelatin wrapped drugs that will dissolve far
quicker.

The shares, which joined AIM at 16p before shooting up on exceptionally
heavy trading to 164p, lost nearly a quarter of their value this week to
end at 112.5p. This is slightly above the institutional placing price and
values the group at around million. The latest deal lowers the stock?s
risk without reducing its growth potential. Buy

I am still holding only wish I could afford more, thanks for the info GF.

March, UK-based, BioProgress has executed an exclusive licensing agreement for its Xgel Tabwrap dosage form technology with a US pharmaceutical company which is a global leader in the OTC medicines and Nutritionals (vitamins, minerals and supplements) product sectors.

The US pharmaceutical company, which remains confidential, has acquired an exclusive license for Tabwrap, one of the BioProgress Xgel dosage forms in a specific market sector and for the territory of North America and the European Union.
BioProgress will receive a payment of US$900,000 upon the first commercialisation and a royalty based on the licensee's sales price of all products which use the Tabwrap dosage form. The Tabwrap technology will initially be applied to a limited number of products which could be on sale before the end of 2005. Sales of the initial group of products, when fully introduced to the US market, are expected to generate royalty income for BioProgress of between $1m and US$1.5m per year. That amount could grow significantly as the Tabwrap technology is applied to higher volume products, new products and introduced into the European market in competition with old tablet coating technology.

The Tabwrap machines will be manufactured under license by the licensee and films for Tabwrap may be supplied to the licensee from the newly acquired BioProgress cGMP film facility in Tampa, Florida USA, generating further revenues and profits for the company.

To ensure that there is the security of multiple supply sources for film in North America, the US pharmaceutical company will also establish a pharmaceutical standard (cGMP) film manufacturing facility to supply their own film requirements under the exclusive license. This second facility will also exclusively supply BioProgress with film, giving BioProgress guaranteed additional cGMP film capacity in the USA as film requirements grow for all BioProgress technologies and customers in the North American market.

BioProgress CEO Graham Hind, said: 'Tabwrap is a technology designed to replace traditional tablet coating techniques by providing a non-gelatin lower-cost, faster, more efficient process. We can also manipulate the dissolution rate of the Tabwrap coating film to increase the dissolution rate of the tablet and add value to products by making the tablet active available to the body faster and facilitating a "faster acting" claim. It also enables a two-colour tablet product presentation not possible with traditional tablet coating methods, offering further product differentiation and marketing advantages over current tablet coating processes. As the Tabwrap film is made from already approved materials and the tablet cores remain unchanged, the regulatory issues are minimal and the technology adoption time and product time to market is relatively short.

'According to IRI, an independent pharmaceutical market monitor, the OTC medicines market in the US is valued at $10.8bn per annum. The European market is also extremely substantial. If our licensee is successful in securing even a modest share of this marketplace through Tabwrap, it is not unrealistic to anticipate that within a few years the BioProgress royalty stream on Tabwrap alone will be very SIGNIFICANT.'

BioProgress Executes New Development Agreement with Global Pharmaceutical Company
ATLANTA, GA (December 19, 2002) - BioProgress Technology International, Inc. (OTC BB: BPRG) today announced it has entered into a Development Agreement with a division of a major pharmaceutical company for several products based on BioProgress' XGel Film technology. The undisclosed company is among the top ten pharmaceutical companies in a ranking of global pharmaceutical sales for 2001. Details regarding the specific products have not been released.

http://www.bioprogress.com/html/news/archive/19-12-02.html

Dated: 9th March 2004

Part of the GH interview

Graham: That relates to another of our technologies, and were in active discussions for that, and what I dont want to do is create a milestone here that I am going to be held accountable for. I would expect that that deal will be concluded in the next few weeks. Its at a stage where most of the major issues, I think, have been resolved but you have to be so careful here. I think people get impatient with us that they did over the last announcement why are they taking so long Where weve got to be extremely careful is when we license, we have a whole range of patents and clearly some overlap into each technology. How we describe this, we have core patents relate to a specific technology Nrobe, Tabletwrap or Septum for example. Then we have what we call the tool kit, which is a whole range, which transcend both. Now obviously these large Companies want to license everything, they want to have everything exclusively and weve got to be extremely careful that we dont inadvertently conclude an agreement which prevents us from licensing another technology because of course every Company dealing with us has their own major patent attorneys who crawl all over it, and its quite complex so its important we do a deal that ensures that it isnt going to interrupt any of our future plans and thats why it often takes a little longer than perhaps we would like because we have to argue this quite vigorously.

Patricia: So exclusivity up to a point?

Graham: Exclusivity to a point; exclusivity that the licensee to be able to have protection but also for us to be able to have the freedom to operate across the broad range of technologies we have. And that does take time, and is complex.


In relation to a Brokers Report:

Graham: .......what we do need is a brokers note and that will come out in the next few weeks, and I didnt really want a note going out until it gave the full picture, clearly there were a lot of exciting things that were about to happen, there was no point in reporting and analysing the Company when youre only looking at 50% of what its potential is. So now, I think, were in a situation where the markets probably need a clear picture of how, what is the revenues potential look like, how big are these
markets, and thats, rather than predict that now Id rather ask you to wait, maybe 2-3 week when well probably come out with a properly considered view.


I like this bit - 'Quote' I would expect that that deal will be concluded in the next few weeks. Its at a stage where most of the major issues, I think, have been resolved but you have to be so careful here.

So do we think we have turned the corner regarding the price being driven down, seems like lots of positive news to come, am still holding for the long term and I personally havent been driven to sell.....

It is sometimes better to travel than arrive.

That's far too obscure for some of the posters on this thread Dil.

Stick in there adie. Checkout what happened to the price when the rights issue was executed. Think we are going to get a similar pattern.

cheers GF.

Wanted to find out more about the timing of the next announcement from BPRG and in my naivety made a few calls. Was told that announcements would be "drip fed" as and when there was actual news and interestingly, told that in May, Spider Man (presumably Spider Man 2) would be released in the US with massive PR INCLUDING aquafilm produced spider man sweetie strips. Any views on the implications for BPRG?
GF?
Anna

by courtesy of Vigilante Man and the MW bb.

'Over the next 10 days or so I'm staring down the barrel of a gun on 3 of my T+ trades so decision time beckoning hence spoke to GH earlier today.
Firstly have to say what an immediately impressive bloke to speak to as he took the time out of his busy schedule to respond to my call without delay.
Without going verbatim I got the confirmation I required that between now and 31 March the broker note will be published preceded by another announcement, and I have a strong feeling this is likely to be next week.

He is acutely aware that the share price is being distorted by the stock being heavily shorted although this should resolve 'very soon'. He went out of his way to assure me that nothing had fundamentally changed since Bio stood at 1.50+ and seems so enthusiastic about the 'multi technologies' yet to come.

Hope this helps anyone hanging in by their fingernails!

Dil
I think the quote is

"To travel hopefully is a better thing than to arrive, and the true success is to labor". - Robert Louis Stevenson

He bought shares in BPRG too did he ?

Dil - I think he went for Stagecoach in the end.....